Matthew Luchini
Stock Analyst at BMO Capital
(2.06)
# 2,940
Out of 4,918 analysts
34
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $7.60 | +294.74% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $2.88 | +6,497.22% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $22.95 | +200.65% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $6.65 | +1,463.91% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $2.12 | +2,494.34% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $7.42 | +1,261.19% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $558.87 | +12.73% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $302.17 | -58.96% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $113.18 | -43.45% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $32.68 | -57.16% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.15 | +5,117.39% | 2 | Dec 3, 2019 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $7.60
Upside: +294.74%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $2.88
Upside: +6,497.22%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $22.95
Upside: +200.65%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $6.65
Upside: +1,463.91%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $2.12
Upside: +2,494.34%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $7.42
Upside: +1,261.19%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $558.87
Upside: +12.73%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $302.17
Upside: -58.96%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $113.18
Upside: -43.45%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $32.68
Upside: -57.16%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.15
Upside: +5,117.39%